机译:低频HIV-1变异体在先前暴露于单剂量奈韦拉平的女性中含奈韦拉平的抗病毒治疗失败中的作用
HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702;
Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115;
Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA02115;
Division of Infectious Disease, University of Pittsburgh, Pittsburgh, PA 15260;
Division of Infectious Disease, University of Pittsburgh, Pittsburgh, PA 15260;
Anova Health Institute, Johannesburg, South Africa;
University of California Los Angeles Care Center, University of California, Los Angeles, CA 90035;
Department of Medicine, University Teaching Hospital, Lusaka, Zambia;
Uniyersity of North Carolina Project-Kamuzu Central Hospital, Lilongwe, Malawi;
Frontier Science and Technology Research Foundation, Amherst, NY 14226;
HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702;
Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115;
HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702;
Division of Infectious Disease, University of Pittsburgh, Pittsburgh, PA 15260;
mother-to-child transmission; nonnucleoside reverse transcriptase inhibitors;
机译:耐奈韦拉平(NVP)的低频HIV-1变异与未事先暴露于单剂量NVP的女性的抗逆转录病毒治疗失败无关
机译:暴露于奈韦拉平的婴儿中稍有抵抗力的变异可能预示着含奈韦拉平的抗病毒药物在病毒学上的失败。
机译:单剂量奈韦拉平治疗预防母婴HIV-1传播后耐奈韦拉平HIV-1的持久性
机译:hiv-1感染的数学分析:参数估计,治疗效果和治疗失败
机译:理解HIV-1进化和潜伏期的计算机和实验方法,用于设计改进的抗病毒治疗
机译:低频HIV-1变异体在先前暴露于单剂量奈韦拉平的女性中含奈韦拉平的抗病毒治疗失败中的作用
机译:低频HIV-1变异体在先前暴露于单剂量奈韦拉平的女性中含奈韦拉平的抗病毒治疗失败中的作用